Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06965569 · ClinicalTrials.gov registry record · Phase 1
Multiple Ascending Dose Phase 1 Study of ALA-3000
A Phase 1 study of Treatment-Resistant Depression, sponsored by Alar Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
- 4
- Study locations
NCT06965569: Completed Phase 1 study of Treatment-Resistant Depression, sponsored by Alar Pharmaceuticals.
NCT06965569 is a Phase 1 study of Treatment-Resistant Depression that has completed, run by Alar Pharmaceuticals. The registered enrollment target is 37 participants, below the 373-participant average among 54 other Treatment-Resistant Depression trials with a reported enrollment target (90% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06965569, a Phase 1 study of Treatment-Resistant Depression, has completed, sponsored by Alar Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a randomized, double-blind, placebo-controlled, multiple-dose study of ALA-3000 designed to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy in subjects with treatment-resistant depression (TRD).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ALA-3000
- DRUG escitalopram, sertraline, duloxetine or venlafaxine XR
Study Locations (4)
Arkansas
- Pillar Clinical Research - Little Rock
Missouri
- Arch Clinical Trials - St Louis
New Jersey
- Clinilabs Drug Development Corporation - Eatontown
Ohio
- Neuro-Behavioral Clinical Research, Inc - North Canton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2025-04-21 |
| Est. Completion | 2025-12-30 |
| Phase | Phase 1 |
What the finished NCT06965569 record still lists
NCT06965569 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 373-participant average among 54 other Treatment-Resistant Depression trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Treatment-Resistant Depression appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06965569 reports a single indexed study location in Arkansas, Missouri, New Jersey.
Frequently Asked Questions
What is clinical trial NCT06965569 about?
NCT06965569 is a clinical study titled "Multiple Ascending Dose Phase 1 Study of ALA-3000". This is a randomized, double-blind, placebo-controlled, multiple-dose study of ALA-3000 designed to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy in subjects with treatment-resistant depression (TRD).
What is the current status of trial NCT06965569?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2025-04-21. Estimated completion is 2025-12-30.
What conditions does trial NCT06965569 study?
This clinical trial studies the following conditions: Treatment-Resistant Depression.
What interventions are being tested in trial NCT06965569?
The interventions under investigation include: Placebo (DRUG), ALA-3000 (DRUG), escitalopram, sertraline, duloxetine or venlafaxine XR (DRUG).
Who is sponsoring clinical trial NCT06965569?
This trial is sponsored by Alar Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06965569 being conducted?
This trial has 4 study locations across Arkansas, Missouri, New Jersey, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Treatment-Resistant Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06965569's enrollment target sits among peer trials
37 35th of 54 higher than 20 of 54 other Treatment-Resistant Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Treatment-Resistant Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
DBS for Depression
RECRUITING · Phase 1
-
Slow Wave Induction by Propofol to Eliminate Depression (SWIPED) I
ACTIVE NOT RECRUITING · Phase 1
-
Safety, Tolerability, PK and Efficacy of Single Doses of NV-5138 in Healthy Volunteers and Subjects With Treatment-Resistant Depression
COMPLETED · Phase 1
-
Home-administered tDCS for Treatment of Depression
COMPLETED · Phase 1
-
Ultrasound Neuromodulation of Circuits and Negative Valence Systems in Treatment-Resistant Depression
RECRUITING · NA
-
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI